Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 18 June 1999:
Vol. 284. no. 5422, pp. 1906 - 1909
DOI: 10.1126/science.284.5422.1906
Prev | Table of Contents | Next

News Focus

HUMAN GENOME:
A High-Stakes Gamble on Genome Sequencing

Eliot Marshall

ROCKVILLE, MARYLAND--J. Craig Venter's commercial venture to sequence the human genome, and those of several other complex organisms, has shaken up the international Human Genome Project. Even as his new company, Celera Genomics, tries to convert raw biology into a business, Venter is promising that he will "give away" one of the first, and most important, fruits of this $300 million-plus venture--the DNA sequence of the human genome. The schedule calls for finishing the human genome--the Holy Grail of the nonprofit Human Genome Project, now in its 10th year--and those of at least three other complex organisms in just 18 months. How can Celera do this and make money?

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Racial Meanings and Scientific Methods: Changing Policies for NIH-Sponsored Publications Reporting Human Variation.
J. Stevens (2003)
Journal of Health Politics Policy and Law 28, 1033-1088
   Abstract »    PDF »
On the sequencing of the human genome.
R. H. Waterston, E. S. Lander, and J. E. Sulston (2002)
PNAS 99, 3712-3716
   Abstract »    Full Text »    PDF »
Estimate of the Mutation Rate per Nucleotide in Humans.
M. W. Nachman and S. L. Crowell (2000)
Genetics 156, 297-304
   Abstract »    Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)